Company: Johnson & Johnson
Headquarters: New Brunswick, NJ
R&D spending fiscal 2011: $7.5 billion
Priorities and Projects: After Johnson & Johnson ($JNJ) decreased its R&D spending slightly from $7 billion in 2009 to $6.8 billion in 2010, the company rebounded in 2011 to $7.5 billion. J&J boasts of research facilities across Europe and North America, as well as in Israel, Japan, Singapore, India and other places. In fact, the company opened an innovation center in China last summer to design and develop medical devices and diagnostic products for Asia's emerging markets--primarily China and India. J&J and its units inked several device-related collaboration agreements in 2011. Metamark Genetics entered an agreement with Janssen Biotech late last year, for example, to identify and characterize proprietary cancer targets that play a causal role in promoting tumor progression and spread. And, once J&J's proposed buyout of Synthes goes through, it could see the development of a host of orthopedic products.
Coming out of 2011 work, J&J's Ortho-Clinical Diagnostics this year announced its development of the Avioq HTLV-I/II Microelisa System assay with Avioq to screen blood and organ donations for antibodies for a virus that, if left undiagnosed, could cause a rare form of leukemia and neurological diseases. In addition, its Veridex business saw the publication of research that could one day lead to a test that would identify individuals at imminent risk of a heart attack. Last year, that same unit said it would work with Massachusetts General Hospital to develop and commercialize a next-generation circulating tumor cell technology for capturing, counting and characterizing tumor cells found in patients' blood. J&J projects that it will remain busy in coming years with projects including the Incraft AAA stent graft for the U.S. and Japan; a next-generation point-of-care testing system for diabetes; next-generation hip and shoulder systems; and numerous assays.